Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development through 3D spatial biology portfolioDynamk CapitalApril 12, 2023
Portfolio Company Vectron Biosolutions Recently Published in Frontiers in Chemical Engineering portfolioDynamk CapitalMarch 20, 2023
Curi Bio Names Nicholas Geisse, Ph.D., as New Chief Executive Officer portfolioDynamk CapitalFebruary 16, 2023
Portfolio Company BitBio Recently Announced a Partnership with Automata portfolioDynamk CapitalFebruary 10, 2023
Portfolio Company Envisagenics enters into Multi-Year Collaboration with BMS portfolioDynamk CapitalNovember 29, 2022
Portfolio Co. Vectron Biosolutions Partners with Plant-Based Foods Manufacturer portfolioDynamk CapitalOctober 26, 2022
Portfolio Co. RoosterBio and AGC Biologics Announce Collaboration portfolioDynamk CapitalAugust 23, 2022
Dynamk Capital Co-Leads $21M Vernal Biosciences round along with Ampersand Capital Partners portfolioDynamk CapitalJune 2, 2022
Bionter AG secures $3 Million in Series Seed Financing Led by Dynamk Capital portfolioDynamk CapitalApril 27, 2022
Portfolio Company Xcellbio expands Labcorp Collaboration for Cell & Gene Therapies portfolioDynamk CapitalApril 21, 2022
Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform portfolioDynamk CapitalSeptember 29, 2021
Lightspeed Microscopy, Inc. raises $4M in Series A Financing Round with Plans to Revolutionize Pathology portfolioDynamk CapitalJune 15, 2021
Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms portfolioDynamk CapitalMarch 18, 2021
CellFE Closes $4.8M Seed Round Funding Co-led by Dynamk Capital and Cota Capital portfolioDynamk CapitalMarch 31, 2020
CellFE Raises $3.6 Million in Series Seed Round Co-Led by Dynamk Capital and Cota Capital portfolioDynamk CapitalJanuary 16, 2020
